AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce

4.8/5 on G2· Since 2015

MeiraGTx Appoints Alan M. Sebulsky as Class I Director

PUBLIC · MGTXSep 23, 2026•about 4 hours ago

Position

Director

Company

MeiraGTx Holdings plc

Alan M. Sebulsky

BiotechnologyHealth CareGeneticsTherapeutics

Description

On September 22, 2026, MeiraGTx Holdings plc appointed Alan M. Sebulsky to the Board as a Class I director. His term will expire at the Company’s 2028 annual meeting of shareholders, consistent with the norm for Class I directors

Company Information

Company

MeiraGTx Holdings plc

Location

States 450 East 29Th Street

About

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular diseases, including both inherited retinal diseases as well as large degenerative ocular diseases, neurodegenerative diseases, and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases. For more information, please visit www.meiragtx.com

Fundz sees it the moment MeiraGTx Holdings plc changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

Sarah

Senior decision-maker at this company

••••••••@••••••••

See Sarah's verified email →

Oliver

Likely contact at this company

••••••••@••••••••

See Oliver's verified email →

Predictive Intelligence

Strategic

ML-powered predictions for MeiraGTx Holdings plc's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

MeiraGTx Holdings plc changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Show me how a recruiter uses this Or see plans and pricing →

5 screens from a live account. No signup.